Table 3.
Characteristic | Group A (AF) | Group B (no AF) | Significance (p) |
---|---|---|---|
157 patients | 191 patients | ||
Gender (male vs female) | p = 0.359 | ||
Male | 137 | 160 | |
Female | 20 | 31 | |
Age | |||
41-55 | 33 | 50 | NS |
56-65 | 56 | 80 | NS |
> 65 | 68 | 61 | p = 0.029 |
Diabetes | 25 | 24 | NS |
History AF | 29 | 19 | p = 0.022 |
History MI | |||
Anterior MI | 41 | 48 | NS |
Posterior MI | 18 | 24 | |
COPD | 28 | 16 | p = 0.008 |
OPA | 19 | 29 | NS |
Unstable angina | 12 | 18 | NS |
Obesity (BMI > 30) | 24 | 19 | NS |
Hypertension | 72 | 79 | NS |
Diseased vessels | |||
CAD-1 | 8 | 11 | NS |
CAD-2 | 26 | 30 | |
CAD-3 | 123 | 147 | |
LMCAD | 16 | 18 | |
E.F | |||
0.30-0.40 | 32 | 21 | p = 0.015 |
0.40-0.55 | 25 | 39 | NS |
> 0.55 | 100 | 131 | NS |
Mild MR | 12 | 10 | NS |
L.A dilation (> 40 mm) | 11 | 15 | |
Proximal stenosis | |||
Proximal LAD | 43 | 38 | NS |
Proximal LCx | 55 | 59 | NS |
Proximal RCA | 42 | 32 | p = 0.023 |
Dyslipidemia | 85 | 104 | NS |
Medical therapy | |||
Nitrates | 137 | 159 | NS |
Β-Blockers | 115 | 143 | |
Ca++- blockers | 68 | 75 | |
Anti-platelets | 131 | 153 |
AF: atrial fibrillation, MI: myocardial infarction, COPD: chronic obstructive pulmonary disease, OPA: obstructive peripheral arteriopathy, BMI: body mass index, CAD: coronary artery disease, E.F: ejection fraction, MR: mitral regurgitation, L.A: left atrium, LAD: left anterior descending artery, LCx: circumflex artery, RCA: right coronary artery. NS: not statistically significant (p > 0.05)